<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Life Science Reit Plc — News on 6ix</title>
<link>https://6ix.com/company/life-science-reit-plc</link>
<description>Latest news and press releases for Life Science Reit Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 07:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/life-science-reit-plc" rel="self" type="application/rss+xml" />
<item>
<title>Cancellation - Life Science REIT plc</title>
<link>https://6ix.com/company/life-science-reit-plc/news/cancellation-life-science-reit-plc</link>
<guid isPermaLink="true">https://6ix.com/company/life-science-reit-plc/news/cancellation-life-science-reit-plc</guid>
<pubDate>Tue, 21 Apr 2026 07:00:00 GMT</pubDate>
<description>Life Science REIT plc's ordinary shares of GBP0.01 each have been cancelled from admission to trading on the London Stock Exchange, effective from April 21, 2026. This cancellation was made at the company's request.
Disclaimer*</description>
</item>
<item>
<title>Disclosure Table</title>
<link>https://6ix.com/company/life-science-reit-plc/news/disclosure-table-44</link>
<guid isPermaLink="true">https://6ix.com/company/life-science-reit-plc/news/disclosure-table-44</guid>
<pubDate>Mon, 20 Apr 2026 06:45:00 GMT</pubDate>
<description>The Takeover Panel has updated its Disclosure Table, noting the commencement of an offer period for Advanced Medical Solutions Group plc by TA Associates (UK), LLP, with a Rule 2.6 deadline of 17:00 on May 16, 2026, and stating that disclosure of dealings and positions in the offeror is not required. Additionally, the offer period for Life Science REIT plc by The British Land Company plc has been deleted, and the offer period for Gamma Communications plc has been amended. Other companies with on</description>
</item>
<item>
<title>Holding(s) in Company</title>
<link>https://6ix.com/company/life-science-reit-plc/news/holdings-in-company-932</link>
<guid isPermaLink="true">https://6ix.com/company/life-science-reit-plc/news/holdings-in-company-932</guid>
<pubDate>Thu, 16 Apr 2026 15:31:00 GMT</pubDate>
<description>UBS Group AG, through UBS AG, has increased its holding in Life Science REIT PLC, crossing a notification threshold on April 15, 2026. The total voting rights now stand at 8.111248%, representing 28,389,369 shares, an increase from the previous notification of 7.086447%. There are no voting rights held through financial instruments.
Disclaimer*</description>
</item>
<item>
<title>Court Sanction of Scheme of Arrangement</title>
<link>https://6ix.com/company/life-science-reit-plc/news/court-sanction-of-scheme-of-arrangement-10</link>
<guid isPermaLink="true">https://6ix.com/company/life-science-reit-plc/news/court-sanction-of-scheme-of-arrangement-10</guid>
<pubDate>Thu, 16 Apr 2026 14:16:00 GMT</pubDate>
<description>Life Science REIT plc announced that the Court has sanctioned the Scheme of Arrangement for its acquisition by The British Land Company PLC. The Scheme is expected to become effective on April 20, 2026, following the delivery of the Court Order to the Registrar of Companies, with trading in Life Science REIT shares expected to be suspended from 7:30 a.m. on April 20, 2026, and cancellation of listing by 8:00 a.m. on April 21, 2026. The Scheme Record Time, determining entitlement to consideration</description>
</item>
<item>
<title>FTSE Russell Index Changes</title>
<link>https://6ix.com/company/life-science-reit-plc/news/ftse-russell-index-changes-1</link>
<guid isPermaLink="true">https://6ix.com/company/life-science-reit-plc/news/ftse-russell-index-changes-1</guid>
<pubDate>Mon, 13 Apr 2026 17:00:00 GMT</pubDate>
<description>FTSE Russell has announced changes to the FTSE UK Index Series, effective from the start of trading on April 20, 2026, contingent upon court sanctioning the scheme of arrangement for British Land Co's acquisition of Life Science REIT. Consequently, Life Science REIT will be removed from the FTSE 100, FTSE 350, FTSE All-Share, FTSE All-Share ex Multinationals, FTSE 350 Higher Yield, FTSE UK Dividend +, FTSE SmallCap, and FTSE All-Small indexes. British Land Co will remain a constituent of these i</description>
</item>
<item>
<title>LBB Specialties and DMC Biotechnologies Partner to Bring Fermented Inositols to the U.S. Market</title>
<link>https://6ix.com/company/life-science-reit-plc/news/lbb-specialties-and-dmc-biotechnologies-partner-to-bring-fermented-inositols-to-the-us-market-1</link>
<guid isPermaLink="true">https://6ix.com/company/life-science-reit-plc/news/lbb-specialties-and-dmc-biotechnologies-partner-to-bring-fermented-inositols-to-the-us-market-1</guid>
<pubDate>Tue, 07 Apr 2026 19:00:00 GMT</pubDate>
<description>LBB Specialties (LBBS), a North American distributor of specialty chemicals and ingredients providing technical solutions with a customer-first approach, today announced a new partnership with DMC Biotechnologies (DMC), a U.S.-based ingredient supplier pioneering sustainable fermentation technologies. Through this agreement, LBB Specialties will serve as the distributor of DMC's KeyPura™ fermented myo-inositol and D-chiro-inositol in the United States and Canada — two next-generation ingredients</description>
</item>
<item>
<title>Merck Completes Acquisition of JSR Life Sciences’ Chromatography Business, Expanding Protein A Capabilities and Downstream Portfolio</title>
<link>https://6ix.com/company/life-science-reit-plc/news/merck-completes-acquisition-of-jsr-life-sciences-chromatography-business-expanding-protein-a-capabilities-and-downstream-portfolio-2</link>
<guid isPermaLink="true">https://6ix.com/company/life-science-reit-plc/news/merck-completes-acquisition-of-jsr-life-sciences-chromatography-business-expanding-protein-a-capabilities-and-downstream-portfolio-2</guid>
<pubDate>Wed, 01 Apr 2026 12:00:00 GMT</pubDate>
<description>Merck Completes Acquisition of JSR Life Sciences’ Chromatography Business Merck Completes Acquisition of JSR Life Sciences’ Chromatography Business Darmstadt, Germany, April 01, 2026 (GLOBE NEWSWIRE) -- Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturingIntegrated downstream workflows to improve productivity and help speed access to critical therapies Merck, a leading science and technology company, today announced that it has succe</description>
</item>
<item>
<title>MilliporeSigma Completes Acquisition of JSR Life Sciences’ Chromatography Business, Expanding Protein A Capabilities and Downstream Portfolio</title>
<link>https://6ix.com/company/life-science-reit-plc/news/milliporesigma-completes-acquisition-of-jsr-life-sciences-chromatography-business-expanding-protein-a-capabilities-and-downstream-portfolio-2</link>
<guid isPermaLink="true">https://6ix.com/company/life-science-reit-plc/news/milliporesigma-completes-acquisition-of-jsr-life-sciences-chromatography-business-expanding-protein-a-capabilities-and-downstream-portfolio-2</guid>
<pubDate>Wed, 01 Apr 2026 12:00:00 GMT</pubDate>
<description>MilliporeSigma Completes Acquisition of JSR Life Sciences’ Chromatography Business MilliporeSigma Completes Acquisition of JSR Life Sciences’ Chromatography Business Burlington, Massachusetts, April 01, 2026 (GLOBE NEWSWIRE) -- Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturingIntegrated downstream workflows to improve productivity and help speed access to critical therapies MilliporeSigma, the U.S. and Canada Life Science business</description>
</item>
<item>
<title>Court and General Meeting Results</title>
<link>https://6ix.com/company/life-science-reit-plc/news/court-and-general-meeting-results-1</link>
<guid isPermaLink="true">https://6ix.com/company/life-science-reit-plc/news/court-and-general-meeting-results-1</guid>
<pubDate>Thu, 19 Mar 2026 13:41:00 GMT</pubDate>
<description>Life Science REIT plc announced that shareholders have approved the recommended cash and share offer by The British Land Company PLC at both the Court Meeting and General Meeting held on March 19, 2026. This significant step means the necessary resolutions for the scheme of arrangement have been passed, with a substantial majority of Scheme Shareholders voting in favour of the scheme and Life Science REIT Shareholders approving the resolution to implement the scheme. The acquisition is now progr</description>
</item>
<item>
<title>Dimensional Fund Advisors Ltd. : Form 8.3 - LIFE SCIENCE REIT PLC - Ordinary Shares</title>
<link>https://6ix.com/company/life-science-reit-plc/news/dimensional-fund-advisors-ltd-form-83-life-science-reit-plc-ordinary-shares</link>
<guid isPermaLink="true">https://6ix.com/company/life-science-reit-plc/news/dimensional-fund-advisors-ltd-form-83-life-science-reit-plc-ordinary-shares</guid>
<pubDate>Tue, 17 Mar 2026 10:34:00 GMT</pubDate>
<description>FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.KEY INFORMATION (a)Full name of discloser:Dimensional Fund Advisors Ltd. whose parent is Dimensional Fund Advisors LP, and also on behalf their investment advisory affiliates (“Dimensional”). The Dimensional entities are investment advisors and Dimensional expressly disclaims beneficial ownership of the shares describe</description>
</item>
<item>
<title>Form 8.3 Life Science REIT Plc</title>
<link>https://6ix.com/company/life-science-reit-plc/news/form-83-life-science-reit-plc-2</link>
<guid isPermaLink="true">https://6ix.com/company/life-science-reit-plc/news/form-83-life-science-reit-plc-2</guid>
<pubDate>Mon, 02 Mar 2026 14:27:00 GMT</pubDate>
<description>8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Rathbones Group Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation</description>
</item>
<item>
<title>Publication of Scheme Document</title>
<link>https://6ix.com/company/life-science-reit-plc/news/publication-of-scheme-document-21</link>
<guid isPermaLink="true">https://6ix.com/company/life-science-reit-plc/news/publication-of-scheme-document-21</guid>
<pubDate>Fri, 20 Feb 2026 07:00:00 GMT</pubDate>
<description>Life Science REIT plc has published a Scheme Document detailing the recommended cash and share offer from The British Land Company PLC, to be implemented via a Scheme of Arrangement. The Life Science REIT Directors unanimously recommend shareholders vote in favour of the acquisition, considering its terms fair and reasonable, with Panmure Liberum providing independent financial advice. The document outlines the full terms, an explanatory statement, meeting notices for a Court Meeting on March 19</description>
</item>
<item>
<title>Form 8.3 - Life Science REIT Plc</title>
<link>https://6ix.com/company/life-science-reit-plc/news/form-83-life-science-reit-plc-1</link>
<guid isPermaLink="true">https://6ix.com/company/life-science-reit-plc/news/form-83-life-science-reit-plc-1</guid>
<pubDate>Thu, 19 Feb 2026 11:55:00 GMT</pubDate>
<description>8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Rathbones Group Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation</description>
</item>
<item>
<title>PraxisPro Raises $6M Seed Round to Transform Life Sciences with AI for Commercial Intelligence</title>
<link>https://6ix.com/company/life-science-reit-plc/news/praxispro-raises-dollar6m-seed-round-to-transform-life-sciences-with-ai-for-commercial-intelligence-1</link>
<guid isPermaLink="true">https://6ix.com/company/life-science-reit-plc/news/praxispro-raises-dollar6m-seed-round-to-transform-life-sciences-with-ai-for-commercial-intelligence-1</guid>
<pubDate>Wed, 21 Jan 2026 14:00:00 GMT</pubDate>
<description>HOUSTON, January 21, 2026--PraxisPro, a data intelligence company rebuilding the fractured state of Life Sciences, today announced the close of its oversubscribed $6M seed round led by AlleyCorp. Additional investors in the round included Flybridge, South Loop Ventures, Zeal Capital Partners, True Ventures, Techstars, Alumni Ventures, and Daring Ventures.</description>
</item>
<item>
<title>Pharma Equity Group executes on the Company's new strategy: Enters into Letter of Intent to acquire the MedTech company Otiom A/S</title>
<link>https://6ix.com/company/life-science-reit-plc/news/pharma-equity-group-executes-on-the-companys-new-strategy-enters-into-letter-of-intent-to-acquire-the-medtech-company-otiom-as-2</link>
<guid isPermaLink="true">https://6ix.com/company/life-science-reit-plc/news/pharma-equity-group-executes-on-the-companys-new-strategy-enters-into-letter-of-intent-to-acquire-the-medtech-company-otiom-as-2</guid>
<pubDate>Wed, 10 Dec 2025 11:17:00 GMT</pubDate>
<description>Pharma Equity Group executes on the Company's new strategy: Enters into Letter of Intent to acquire the MedTech company Otiom A/S Copenhagen, 10 December 2025 Company Announcement no. 15 Pharma Equity Group A/S ("PEG") today announces that the company has signed a Letter of Intent regarding the acquisition of the entire share capital or a majority stake in Otiom A/S. The transaction marks the first concrete step in PEG’s expanded strategy to become a leading consolidator within Life Science, spa</description>
</item>
<item>
<title>The Inception Company and Data360 Announce Strategic Partnership to Transform HCP Engagement Through Dynamic Digital Events</title>
<link>https://6ix.com/company/life-science-reit-plc/news/the-inception-company-and-data360-announce-strategic-partnership-to-transform-hcp-engagement-through-dynamic-digital-events</link>
<guid isPermaLink="true">https://6ix.com/company/life-science-reit-plc/news/the-inception-company-and-data360-announce-strategic-partnership-to-transform-hcp-engagement-through-dynamic-digital-events</guid>
<pubDate>Mon, 10 Nov 2025 14:08:00 GMT</pubDate>
<description>The Inception Company, the market leader in live, virtual, and hybrid HCP event experiences, and Data360, Inc., the healthcare industry's leading provider of Identity-First and Intent-Fueled Solutions, today announced a strategic partnership that redefines how healthcare professionals (HCPs) are engaged across digital platforms.</description>
</item>
<item>
<title>Alliance for Building Better Medicine and the Virginia Innovation Partnership Celebrate $120 Million Investment from AstraZeneca, Eli Lilly, and Merck to Advance Virginia's Advanced Pharmaceutical Manufacturing Workforce</title>
<link>https://6ix.com/company/life-science-reit-plc/news/alliance-for-building-better-medicine-and-the-virginia-innovation-partnership-celebrate-dollar120-million-investment-from-astrazeneca-eli-lilly-and-merck-to-advance-virginias-advanced-pharmaceutical-manufacturing-workforce-1</link>
<guid isPermaLink="true">https://6ix.com/company/life-science-reit-plc/news/alliance-for-building-better-medicine-and-the-virginia-innovation-partnership-celebrate-dollar120-million-investment-from-astrazeneca-eli-lilly-and-merck-to-advance-virginias-advanced-pharmaceutical-manufacturing-workforce-1</guid>
<pubDate>Wed, 05 Nov 2025 19:26:00 GMT</pubDate>
<description>The Alliance for Building Better Medicine (ABBM) and the Virginia Innovation Partnership Corporation (VIPC) celebrated Governor Glenn Youngkin's announcement of $120 million in private industry investment from AstraZeneca, Eli Lilly, and Merck to establish the Virginia Center for Advanced Pharmaceutical Manufacturing (APM) in the Richmond-Petersburg-Charlottesville region. This neutral, industry-led Center will expand Virginia's workforce and training pipeline in collaboration with university an</description>
</item>
<item>
<title>NNIT A/S: NNIT restates its life science segment in its financial reporting structure</title>
<link>https://6ix.com/company/life-science-reit-plc/news/nnit-as-nnit-restates-its-life-science-segment-in-its-financial-reporting-structure-3</link>
<guid isPermaLink="true">https://6ix.com/company/life-science-reit-plc/news/nnit-as-nnit-restates-its-life-science-segment-in-its-financial-reporting-structure-3</guid>
<pubDate>Wed, 29 Oct 2025 13:00:00 GMT</pubDate>
<description>Today, NNIT announces an update to its financial reporting structure to ensure that all Life Sciences customers are fully consolidated under Region Europe, US, and Asia. As a result, all Life Science customers previously reported under Region Denmark irrespective of the business activity will now be included in Region Europe’s profit and loss statement. Going forward, Region Denmark will consist solely of the Public segment and the Private segment, which includes SCALES. The restatement of the L</description>
</item>
<item>
<title>MilliporeSigma Partners with Promega to Advance 3-D Cell Drug Discovery Technologies</title>
<link>https://6ix.com/company/life-science-reit-plc/news/milliporesigma-partners-with-promega-to-advance-3-d-cell-drug-discovery-technologies-2</link>
<guid isPermaLink="true">https://6ix.com/company/life-science-reit-plc/news/milliporesigma-partners-with-promega-to-advance-3-d-cell-drug-discovery-technologies-2</guid>
<pubDate>Tue, 28 Oct 2025 12:00:00 GMT</pubDate>
<description>BURLINGTON, Mass., October 28, 2025--MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, has entered into a partnership with Promega Corporation, a global life science solutions and service leader based in Madison, Wisconsin, to co-develop novel technologies that advance drug screening and discovery.</description>
</item>
<item>
<title>MilliporeSigma to Acquire Chromatography Business of JSR Life Sciences, Expanding Protein A Capabilities and Downstream Portfolio</title>
<link>https://6ix.com/company/life-science-reit-plc/news/milliporesigma-to-acquire-chromatography-business-of-jsr-life-sciences-expanding-protein-a-capabilities-and-downstream-portfolio-2</link>
<guid isPermaLink="true">https://6ix.com/company/life-science-reit-plc/news/milliporesigma-to-acquire-chromatography-business-of-jsr-life-sciences-expanding-protein-a-capabilities-and-downstream-portfolio-2</guid>
<pubDate>Wed, 15 Oct 2025 13:03:00 GMT</pubDate>
<description>BURLINGTON, Mass., October 15, 2025--MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that the Life Science business of Merck KGaA, Darmstadt, Germany has signed a definitive agreement to acquire the chromatography business of JSR Life Sciences, a leader in contract development and manufacturing, preclinical and translational clinical research, and bioprocessing solutions. The acquisition will e</description>
</item>
</channel>
</rss>